About the Company
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
10007
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on ILLUMINA, INC.
Does Illumina (ILMN) have an Attractive Risk-Reward Opportunity for Long-Term Investors?
Baron Funds, an investment management company, released its “Baron Global Advantage Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. In the second ...
Illumina fined $9.8M for selling DNA sequencers with cybersecurity flaws to U.S. agencies
Illumina Inc., a leading biotechnology company, has agreed to pay $9.8 million to settle allegations that it sold genomic sequencing systems with serious cybersecurity flaws to U.S. federal agencies.
Illumina wins fast-track appeal of FTC order to offload Grail
The case is Illumina Inc and Grail Inc v. Federal Trade Commission, 5th U.S. Circuit Court of Appeals, No. 23-60167. For Illumina: David Marriott and Christine Varney of Cravath, Swaine & Moore ...
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $1.19 per share which beat the analyst consensus estimate of ...
Illumina, Inc. (ILMN) - Yahoo Finance
Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven ...
Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025
Illumina, Inc. (NASDAQ:ILMN) stock is down 35.88% year-to-date. Overall ILMN ranks 3rd on our list of the large-cap stocks that are plunging so far in 2025.
DOJ Sharpens Focus on Cybersecurity Compliance in Healthcare: Illumina FCA Settlement Signals Broader Trend
On July 31, 2025, the U.S. Department of Justice announced that Illumina Inc. agreed to pay $9.8 million to resolve False Claims Act ...
Illumina, Inc. (ILMN) Investor Notice: Robbins LLP Reminds Investors of ...
Illumina, Inc. (ILMN) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Illumina, Inc. November 15, 2023 01:01 PM Eastern Standard Time ...
At the Crossroads: Illumina Settlement Reflects the Intersection of Cybersecurity and Healthcare Law
On July 31, the U.S. Department of Justice (DOJ) announced a settlement in United States ex rel. Lenore v. Illumina, Inc, the first case in ...
Illumina hit with $9.8M fine for unsecure sequencing equipment
The U.S. Department of Justice announced July 31 that Illumina Inc. agreed to pay $9.8 million to settle allegations it sold genomic sequencing equipment that suffered from cybersecurity problems. The ...
FTC resists Illumina's push for more experts at merger trial
The case is In the Matter of Illumina Inc and Grail Inc, Federal Trade Commission Office of Administrative Law Judges, Docket No. 9401. For the government: Susan Musser and Wells Harrell of the FTC ...
Illumina, Inc. and the Illumina Corporate Foundation Commit ... - Nasdaq
Illumina, Inc. is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. To support public health ...
Similar Companies
Loading the latest forecasts...